DAD CALCULATION WORKSPACE

Design the dose architecture.

Deterministic, traceable calculations for device-achievable doses, band-specific combination-product tolerances, capacity, and adjacent-dose overlap.

Create the Original Dose Design first. Dose overlap is calculated separately and does not influence initial dose generation.

Basic parameter levelChoose Fixed, Preferred (±45%), Flexible (±90%), or Free for every numeric parameter.

INPUTS

Design parameters

Band 1 is the master. New bands inherit Band 1; a secondary-band edit detaches only that parameter. All graph results use these same band states.

Entered / inheritedAdjusted to resolve a conflictUnresolved Fixed conflict

Project information

Project ID

Used in saved designs and reports.

Project manager

Date

Dose-design method

Dose-design starting pointDaily-dose inputs and conversion are not applicable. The system optimizes unknown dose positions and permitted parameters.

Dose-band setup

Number of dose bands

count

Select 1–5 ordered dose bands.

Active dose band

B1 Master

Each band has its own ordered dose range, concentration, increment, tolerances, and capacity. At an interface, the last dose of the lower band and first dose of the higher band keep their own ranges; overlap is assessed later using the selected Device, Release, or EOSL basis.

Project and dose architecture · Band 1

Each numeric input can be Fixed, Preferred (maximum ±45%), Flexible (maximum ±90%), or Free with no requested target. When both Preferred and Flexible values move, the optimizer targets approximately twice the percentage movement for Flexible items. Advanced mode also exposes physical minimum and maximum bounds.

Minimum desired dose

Maximum desired dose

Drug concentration

Number of doses

count

Specifying dose count creates equal absolute spacing.

Dose-generation method

Device accuracy and ISO boundary · Band 1

NIS dose typeISO 11608-1 system designation

Minimum device increment

Adjusted value: 5 µL

ISO absolute error α

µL

Variable-dose α is linked to this band’s device increment.

Calculated transition point PT

µL

PT = α / 0.05; recalculates immediately when this band’s increment changes.

Device lower tolerance ≤ PT

µL

Adjusted value: 5 µL

Device upper tolerance ≤ PT

µL

Adjusted value: 5 µL

Device lower tolerance > PT

Adjusted value: 5 %

Device upper tolerance > PT

Adjusted value: 5 %

Accuracy modelCompliance mode

Device tolerances and selected ISO model are aligned.

Drug concentration tolerance · Band 1

Release lower

Adjusted value: -2 %

Release upper

Adjusted value: 2 %

EoSL lower

Adjusted value: -4 %

EoSL upper

Adjusted value: 4 %

Drug limits are evaluated separately at Release and End of shelf life. The worse scenario is reported as governing, but both remain visible.

Capacity and priming · Band 1

Container fill volume

Adjusted value: 3 mL

Required dose uses

count

Adjusted value: 4 count

Injections per dose

count

Adjusted value: 1 count

Priming volume per event

Adjusted value: 0.1 mL

Container fill sourceFull-container evacuation

Priming frequency

Residual / dead volume

Measured/project input; counted once.

Adjusted value: 0 mL

Engineering reserve

Project input; counted once.

Adjusted value: 0 mL

Last-dose accuracy assessment

Required fill = dose volume × injections per dose × dose uses + priming events × priming/event + residual/dead + reserve. Priming frequency determines event count.

Each parameter appears once in its category. Fixed values cannot move; Preferred allows up to ±45%, Flexible up to ±90%, and Free has no requested target. Advanced mode exposes minimum and maximum bounds. Adjusted Value shows the actual value used.

Comments and warnings9Open to view details

Band 1: complete the last-dose accuracy assessment required for variable-dose A/C systems.

Band 1: an absolute device tolerance exceeds 5% of a dose volume below PT.

Band 1: residual/dead volume is zero; confirm it is measured or justified.

Band 1: engineering reserve is zero; confirm that no reserve is required.

Band 1: Residual / dead volume starts at zero; define a non-zero absolute minimum/maximum range before allowing optimization.

Band 1: Engineering reserve starts at zero; define a non-zero absolute minimum/maximum range before allowing optimization.

Band 1: Maximum dose variation overlap starts at zero; define a non-zero absolute minimum/maximum range before allowing optimization.

At least one Release adjacent-range intersection exceeds the maximum overlap limit of its governing higher band.

At least one End-of-shelf-life adjacent-range intersection exceeds the maximum overlap limit of its governing higher band.

LIVE RESULT

Architecture visualization

9 doses · 1 ordered dose band · 0 fixed dose adjustments

Overlap basis

Both graph views use the same all-band total combination-product calculations.

Overlap uses the complete Release delivered-dose ranges.

EOSL (Delivered Dose) rangeRelease (Delivered Dose) rangeDevice (Volume) Variation rangeDose variation overlapDose Band 1

Number of doses: 9Capacity: B1 PassISO device boundary: B1 Pass · Active PT 100.0 µLActive priming: 1 × 0.100 mLDose variation overlap: 1.14 µg / limit 0.00 µg · 38.0% · B1 · D8 → B1 · D9

OPTIONAL SECOND STAGE

Dose-overlap optimization

▲

First review the Original Dose Design. Then optionally reduce and redistribute doses using one delivered-dose range.

Optimization methodOverlap basis

Permitted minimum-dose endpoint change

Default 0%. Used only if moving the minimum retains a larger feasible dose count.

Permitted maximum-dose endpoint change

Default 0%. Used only if moving the maximum retains a larger feasible dose count.

Priority: maximize dose count; keep both endpoints unchanged; then keep minimum unchanged; then keep maximum unchanged; finally move both by the smallest permitted percentages. Multiple dose bands are optimized as one continuous system. Intermediate band maxima stay fixed as rule thresholds: an Actual Dose at or below a threshold uses the lower band, while a dose above it uses the higher band. Every dose and interface pair is therefore calculated with its applicable band's concentration, increment, device, drug, and ISO parameters. The minimum permitted optimized spacing is measured from the smallest adjacent Actual-Dose gap across the complete Original Dose Design, including band interfaces; a single percentage design uses its smallest original Actual-Dose percentage gap.

No dose selected

Click a dose marker or table row to inspect it. Click empty graph space to clear the selection.

All doses · Desired and Actual values, both scenarios, and adjacent dose variation overlap

Interface limit is governed by the higher band

DOSE	DESIRED DOSE	ACTUAL DOSE	VOLUME	DESIRED INCREMENT	RELEASE RANGE	EOSL RANGE	OVERLAP / SEVERITY	STATE
B1D1	6.00 µg	6.00 µg	20.00 µL	—	4.41 µg–7.65 µg	4.32 µg–7.80 µg	—	Calculated
B1D2	9.00 µg	9.00 µg	30.00 µL	3.00 µg · 50.0%	7.35 µg–10.71 µg	7.20 µg–10.92 µg	0.30 µg · 10.0%R 0.30 µg · E 0.60 µg	Review
B1D3	12.00 µg	12.00 µg	40.00 µL	3.00 µg · 33.3%	10.29 µg–13.77 µg	10.08 µg–14.04 µg	0.42 µg · 14.0%R 0.42 µg · E 0.84 µg	Review
B1D4	15.00 µg	15.00 µg	50.00 µL	3.00 µg · 25.0%	13.23 µg–16.83 µg	12.96 µg–17.16 µg	0.54 µg · 18.0%R 0.54 µg · E 1.08 µg	Review
B1D5	18.00 µg	18.00 µg	60.00 µL	3.00 µg · 20.0%	16.17 µg–19.89 µg	15.84 µg–20.28 µg	0.66 µg · 22.0%R 0.66 µg · E 1.32 µg	Review
B1D6	21.00 µg	21.00 µg	70.00 µL	3.00 µg · 16.7%	19.11 µg–22.95 µg	18.72 µg–23.40 µg	0.78 µg · 26.0%R 0.78 µg · E 1.56 µg	Review
B1D7	24.00 µg	24.00 µg	80.00 µL	3.00 µg · 14.3%	22.05 µg–26.01 µg	21.60 µg–26.52 µg	0.90 µg · 30.0%R 0.90 µg · E 1.80 µg	Review
B1D8	27.00 µg	27.00 µg	90.00 µL	3.00 µg · 12.5%	24.99 µg–29.07 µg	24.48 µg–29.64 µg	1.02 µg · 34.0%R 1.02 µg · E 2.04 µg	Review
B1D9	30.00 µg	30.00 µg	100.00 µL	3.00 µg · 11.1%	27.93 µg–32.13 µg	27.36 µg–32.76 µg	1.14 µg · 38.0%R 1.14 µg · E 2.28 µg	Review

Calculation basisDesired Dose is the entered or optimized target. Actual Dose is the closest device-achievable value based on concentration and available volume increment.

Overlap and ISO contextMaximum overlap uses the complete adjacent delivered-dose range intersection. The higher band governs an interface. Active Band 1 PT is 100.0 µL.

MAX OVERLAP · RELEASE1.14 µg38.0% of Actual Dose separation · B1 · D8 → B1 · D9

MAX OVERLAP · EOSL2.28 µg76.0% of Actual Dose separation · B1 · D8 → B1 · D9

CAPACITY · ALL BANDSAll bands passB1: 0.500 / 3.000 mL

SYSTEM STATUSOverlap above limitEnd of shelf life is the governing scenario · ISO device boundaries met

ASSUMPTIONS & FORMULAS

Transparent calculation chain

Band setupBand 1 is master; each later band starts as a copy and edits detach only the changed parameter.

Band target gridEach band generates its own Desired Doses from its minimum, maximum, count, and rule.

Actual DoseFeasible volume × that band’s drug concentration

Feasible volumeROUND((target dose ÷ concentration) ÷ increment) × increment

ISO transitionPT = α ÷ 0.05; variable-dose α is the band’s device increment

Total combination rangeLower/upper device volume × lower/upper drug concentration for Release or EoSL

Dose variation overlapMAX(0, MIN(upper A, upper B) − MAX(lower A, lower B))

Overlap percentageOverlap width ÷ (Actual Dose B − Actual Dose A) × 100; equal Actual doses report “-”.

Overlap optimizationCalculate searches feasible non-Fixed architecture candidates and minimizes the system maximum adjacent total-dose overlap across Release and EoSL; ties favor the closest requested design.

Interface ruleBoundary doses keep their own ranges; the higher dose band supplies the overlap acceptance limit.

ISO 11608-1 is treated as a minimum boundary. Better performance is allowed; worse performance is visibly flagged. This screening tool does not make a regulatory compliance determination.

DESIGN HISTORY

Save and compare up to three systems

History includes all dose bands, parameters, detached states, Actual Doses, Release/EoSL maxima, capacity, and ISO status.

No saved designs yet. Save the current system to create a comparison record.

CP DESIGN LAB · PRINT REPORT

DAD-PROTOTYPE-01

Generated 11/6/2026, 9:49:37 PM · 1 dose band(s) · Governing scenario: End of shelf life

ProjectManager —Date 1970-01-011 ordered dose band(s) · 9 total doses

Band summariesB1: 6–30 µg · 0.3 µg/µL · 5 µL increment

Calculated dose table

Dose	Desired Dose	Actual Dose	Volume	Release range	EoSL range
B1 · D1	6.00 µg	6.00 µg	20.00 µL	4.41–7.65 µg	4.32–7.80 µg
B1 · D2	9.00 µg	9.00 µg	30.00 µL	7.35–10.71 µg	7.20–10.92 µg
B1 · D3	12.00 µg	12.00 µg	40.00 µL	10.29–13.77 µg	10.08–14.04 µg
B1 · D4	15.00 µg	15.00 µg	50.00 µL	13.23–16.83 µg	12.96–17.16 µg
B1 · D5	18.00 µg	18.00 µg	60.00 µL	16.17–19.89 µg	15.84–20.28 µg
B1 · D6	21.00 µg	21.00 µg	70.00 µL	19.11–22.95 µg	18.72–23.40 µg
B1 · D7	24.00 µg	24.00 µg	80.00 µL	22.05–26.01 µg	21.60–26.52 µg
B1 · D8	27.00 µg	27.00 µg	90.00 µL	24.99–29.07 µg	24.48–29.64 µg
B1 · D9	30.00 µg	30.00 µg	100.00 µL	27.93–32.13 µg	27.36–32.76 µg

Formulas and warnings

Overlap width = MAX(0, MIN(upper A, upper B) − MAX(lower A, lower B)); overlap percentage = overlap width ÷ (Actual Dose B − Actual Dose A) × 100, or “-” when Actual Doses are equal. Band 1: complete the last-dose accuracy assessment required for variable-dose A/C systems. Band 1: an absolute device tolerance exceeds 5% of a dose volume below PT. Band 1: residual/dead volume is zero; confirm it is measured or justified. Band 1: engineering reserve is zero; confirm that no reserve is required. Band 1: Residual / dead volume starts at zero; define a non-zero absolute minimum/maximum range before allowing optimization. Band 1: Engineering reserve starts at zero; define a non-zero absolute minimum/maximum range before allowing optimization. Band 1: Maximum dose variation overlap starts at zero; define a non-zero absolute minimum/maximum range before allowing optimization. At least one Release adjacent-range intersection exceeds the maximum overlap limit of its governing higher band. At least one End-of-shelf-life adjacent-range intersection exceeds the maximum overlap limit of its governing higher band.